7 unknown, 5 recruiting, 4 not yet recruiting, 1 active not recruiting. 8 Phase 1, 7 Phase 2, 2 Phase 4, 1 Not applicable.
Follow relmacabtagene autoleucel: new trials by email Literature Review of relmacabtagene autoleucel trials Research Report on relmacabtagene autoleucel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glofitamab Combined With CAR-T Therapy in R/R DLBCL Glofitamab, Obinutuzumab, Axicabtagene Ciloleucel - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 24 | 2026-03-01 | 2026-01-08 |
| Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma Relmacabtagene autoleucel and transplantation - Primary Central Nervous System Lymphoma (PCNSL) | Not applicable | Not yet recruiting | Zhengzhou University | 30 | 2025-10-07 | 2025-09-30 |
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor) - Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 30 | 2025-09-15 | 2026-01-21 |
| CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma Relma-cel - Non-Hodgkin Lymphoma, Large B-cell Lymphoma | Phase 2 | Recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 12 | 2024-08-15 | 2024-08-21 |
| Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis Relma-cel - Systemic Sclerosis | Phase 1 | Recruiting | Liangjing Lu | 6 | 2024-06-12 | 2024-08-15 |
| CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors autologous stem-cell transplantation, Relmacabtagene autoleucel (relma-cel) - B-cell Non Hodgkin Lymphoma | Phase 2 | Recruiting | Ruijin Hospital | 16 | 2024-04-16 | 2026-01-06 |
| Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus Relma-cel - Systemic Lupus Erythematosus | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 24 | 2024-03-01 | 2024-03-07 |
| Relmacabtagene Autoleucel in Hematologic Malignancies Relmacabtagene Autoleucel - Lymphoma, B-Cell, Large B-cell Lymphoma | Not yet recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 150 | 2023-12-28 | 2023-11-21 | |
| Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B | Phase 2 | Active not recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 46 | 2023-11-03 | 2025-02-11 |
| A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma Relmacabtagene Autoleucel Injection - Relapsed or Refractory B-cell Lymphoma | Phase 4 | Not yet recruiting | Changhai Hospital | 13 | 2023-06-20 | 2023-06-15 |
| Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma Relma-cel - Relapsed or Refractory B-cell Lymphoma | Phase 4 | Recruiting | Ruijin Hospital | 8 | 2023-05-01 | 2024-10-23 |
| CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus Relma-cel - Systemic Lupus Erythematosus | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 24 | 2023-02-24 | 2023-03-15 |
| Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - B-cell Lymphoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 20 | 2023-01-03 | 2024-01-08 |
| Relmacabtagene Autoleucel in Patients With LBCL Relmacabtagene Autoleucel - Large B-cell Lymphoma | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 200 | 2022-12-28 | 2024-03-28 | |
| Chidamide Bridging for CAR-T Therapy Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells - Non Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 120 | 2022-05-25 | 2024-03-06 |
| Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL JWCAR029 (Relmacabtagene Autoleucel) - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Withdrawn | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-02-28 | 2023-11-24 | |
| CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) - Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Shanghai Ming Ju Biotechnology Co., Ltd. | 12 | 2020-07-10 | 2023-11-22 |
| Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma JWCAR029 - Non Hodgkin Lymphoma | Phase 1 | Unknown | Zhao Weili | 10 | 2018-01-05 | 2019-07-12 |
| Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma JWCAR029 - Non Hodgkin Lymphoma | Phase 1 | Unknown | Peking University | 20 | 2017-11-16 | 2019-07-12 |
Lymphoma, B-Cell (6) · Lymphoma, Non-Hodgkin (4) · Lymphoma, Large B-Cell, Diffuse (3) · Recurrence (3) · Lupus Erythematosus, Systemic (2) · Lymphoma, Follicular (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Scleroderma, Systemic (1)
Shanghai Ming Ju Biotechnology Co., Ltd. (8) · Ruijin Hospital (3) · Changhai Hospital (1) · Chinese PLA General Hospital (1) · Liangjing Lu (1) · Peking University (1) · Peking University Cancer Hospital & Institute (1) · Sun Yat-sen University (1) · Zhao Weili (1) · Zhengzhou University (1)
China (15)
Huilai Zhang (2) · Weili Zhao, PhD (2) · Dehui Zou (1) · Depei Wu (1) · Depei Wu, PhD (1) · Heng Mei (1) · Hongmei Jing (1) · Huiqiang Huang, PhD (1) · JianYong Li (1) · Jianqiu Wu (1) · Li Chen (1) · Liang Huang, PhD (1) · Liangjing Lu (1) · Ping Li (1) · Qingyuan Zhang (1)
PMID 34515338, PMID 3005930, PMID 31444250, PMID 36109639, PMID 40386685